EQRx Inc. [NASDAQ: EQRX] stock went on a downward path that fall over -2.00% on Friday, amounting to a one-week price increase of more than 6.74%. The company report on June 14, 2022 that EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Marketing authorization application is EQRx’s first submission to a regulatory agency.
Application is based on data from pivotal Phase 3 AENEAS trial in the first-line treatment of EGFR-mutated non-small cell lung cancer.
Over the last 12 months, EQRX stock dropped by -51.63%. The one-year EQRx Inc. stock forecast points to a potential upside of 27.79. The average equity rating for EQRX stock is currently 1.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $2.44 billion, with 470.63 million shares outstanding and 407.89 million shares in the current float. Compared to the average trading volume of 1.64M shares, EQRX stock reached a trading volume of 20515001 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on EQRx Inc. [EQRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EQRX shares is $6.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EQRX stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for EQRx Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 13, 2022. While these analysts kept the previous recommendation, Cowen raised their target price to Outperform. The new note on the price target was released on April 22, 2022, representing the official price target for EQRx Inc. stock. Previously, the target price had yet another raise to $5.60, while Jefferies analysts kept a Buy rating on EQRX stock.
The Average True Range (ATR) for EQRx Inc. is set at 0.51 The Price to Book ratio for the last quarter was 1.49, with the Price to Cash per share for the same quarter was set at 3.26.
EQRX Stock Performance Analysis:
EQRx Inc. [EQRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.74. With this latest performance, EQRX shares gained by 14.19% in over the last four-week period, additionally sinking by -28.43% over the last 6 months – not to mention a drop of -51.63% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EQRX stock in for the last two-week period is set at 54.61, with the RSI for the last a single of trading hit 56.02, and the three-weeks RSI is set at 53.74 for EQRx Inc. [EQRX]. The present Moving Average for the last 50 days of trading for this stock 4.53, while it was recorded at 5.02 for the last single week of trading, and 6.47 for the last 200 days.
Insight into EQRx Inc. Fundamentals:
EQRx Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 29.20 and a Current Ratio set at 29.20.
EQRx Inc. [EQRX] Insider Position Details
There are presently around $1,434 million, or 59.70% of EQRX stock, in the hands of institutional investors. The top three institutional holders of EQRX stocks are: SB MANAGEMENT LTD with ownership of 43,176,600, which is approximately 0% of the company’s market cap and around 16.38% of the total institutional ownership; CASDIN CAPITAL, LLC, holding 39,527,669 shares of the stock with an approximate value of $194.08 million in EQRX stocks shares; and ARCH VENTURE MANAGEMENT, LLC, currently with $178.41 million in EQRX stock with ownership of nearly 0% of the company’s market capitalization.
56 institutional holders increased their position in EQRx Inc. [NASDAQ:EQRX] by around 29,292,996 shares. Additionally, 19 investors decreased positions by around 11,055,142 shares, while 26 investors held positions by with 251,708,839 shares. The mentioned changes placed institutional holdings at 292,056,977 shares, according to the latest SEC report filing. EQRX stock had 37 new institutional investments in for a total of 15,595,870 shares, while 11 institutional investors sold positions of 6,895,153 shares during the same period.